Buy Vortioxetine (Trintellix) Cas 508233-74-7

Vortioxetine, sold under the brand names Trintellix (in the US) and Brintellix (in Europe) among others, is an antidepressant medication of the serotonin modulator and stimulator (SMS) class used in the treatment of major depressive disorder.^[14][3] Its effectiveness is viewed as similar to that of other antidepressants.^[14] It is taken orally.^[14]

Common side effects include nausea, dry mouth, diarrhea, constipation, vomiting (3-6% of people), and sexual dysfunction.^[14][10] Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and SIADH.^[14] A withdrawal syndrome may occur if the medication is abruptly stopped or the dose is decreased.^[14] Use during pregnancy and breastfeeding is not generally recommended.^[15] Vortioxetine’s mechanism of action is not entirely understood, but is believed to be related to increasing serotonin levels and possibly interacting with certain serotonin receptors.^[14][16][17]

It was approved for medical use in the United States^[18][14][19] and in the European Union in 2013.^[11] In 2020, it was the 243rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.^[20][21]

Vortioxetine is used as a treatment for major depressive disorder,^[14] with its effectiveness shown to be similar to other antidepressants^[14][22][23] and its effect size has been described as modest.^[24] Vortioxetine may be used when other treatments have failed.^{[10][25][26][27]} A 2017 Cochrane review on vortioxetine determined that its place in the treatment of severe depression is unclear due to low-quality evidence and that more studies comparing vortioxetine to selective serotonin reuptake inhibitors (SSRIs), the typical first-line treatments, are needed.^[28] Vortioxetine appears to work in depressed patients with anxiety.^[29]

Vortioxetine is also used off label for anxiety.^[30] A 2016 review found it was not useful in generalized anxiety disorder at 2.5, 5.0, and 10 mg doses (15 and 20 mg doses were not tested).^[31] A 2019 meta-analysis found that vortioxetine did not produce statistically significant results over placebo in the symptoms, quality of life, and remission rates of generalized anxiety disorder, but it was well-tolerated.^[32] However, a 2018 meta-analysis supported use and efficacy of vortioxetine for generalized anxiety disorder, though stated that more research was necessary to strengthen the evidence.^[33] A 2021 systematic review and meta-analysis concluded that there was uncertainty about the effectiveness of vortioxetine for anxiety due to existing evidence being of very low-quality.^[34] In a 2020 network meta-analysis of randomized controlled trials, vortioxetine was among the lowest remission rates for generalized anxiety disorder of the included medications (odds ratio = 1.30 for vortioxetine, range of odds ratios for other agents = 1.13–2.70).^[35]